Loss of Lantus sales to U.S. biosimilars 2015-2017
This statistic depicts the sales of Lantus from 2015 to 2017 compared to the sales of its U.S. biosimilar competitor . In 2015, Lantus generated 3.76 billion U.S. dollars in sales while Basaglar generated no sales. As of November 2017, Lantus sales dropped to 2.39 billion U.S. dollars and Basaglar sales increased to 558.1 million U.S. dollars.